Who is sponsoring NCT06047210?

NCT06047210 is sponsored by Swedish Orphan Biovitrum.

What drugs are being tested in NCT06047210?

Interventions in NCT06047210: Blood Draws Data Collection.

What condition does NCT06047210 study?

NCT06047210 studies Hemophagocytic Lymphohistiocytoses.

Is NCT06047210 still recruiting?

NCT06047210 is currently completed. Last updated 19 September 2024.

Are results published for NCT06047210?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-19 · How we verify

NCT06047210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Completed Results posted Last updated 19 September 2024

What this trial tests

trial testing Blood Draws Data Collection in Hemophagocytic Lymphohistiocytoses in 14 participants. Completed in 30 October 2019.

Timeline

14 December 2016

Primary endpoint
30 October 2019

30 October 2019

Quick facts

Lead sponsor	Swedish Orphan Biovitrum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	14
Start date	14 December 2016
Primary completion	30 October 2019
Estimated completion	30 October 2019
Sites	1 location across United States

Drugs / interventions tested

Blood Draws Data Collection

Conditions studied

Hemophagocytic Lymphohistiocytoses — all drugs for Hemophagocytic Lymphohistiocytoses →

Sponsor

Swedish Orphan Biovitrum — full company profile →

Who can join

18 and older, any sex, with Hemophagocytic Lymphohistiocytoses. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.

Group	Value	95% CI
A-HLH Patients	2079.286	± 2659.228
M-HLH Patients	15197.143	± 21288.948

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9.

Group	Value	95% CI
A-HLH Patients	4474.685	± 10207.638
M-HLH Patients	6602.853	± 7777.846

Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg.

Group	Value	95% CI
A-HLH Patients	81.782	± 140.870
M-HLH Patients	809.810	± 769.433

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10.

Group	Value	95% CI
A-HLH Patients	24.157	± 87.640
M-HLH Patients	266.948	± 257.770

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B.

Group	Value	95% CI
A-HLH Patients	2.140	± 0.000
M-HLH Patients	2.140	± 0.000

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6.

Group	Value	95% CI
A-HLH Patients	3.455	± 3.727
M-HLH Patients	29.695	± 52.403

Mean Serum Concentration of Inflammatory Biomarker - Neopterin Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.

Group	Value	95% CI
A-HLH Patients	33.995	± 29.227
M-HLH Patients	839.775	± 950.070

Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa.

Group	Value	95% CI
A-HLH Patients	6.050	± 6.405
M-HLH Patients	14.308	± 12.010

Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg.

Group	Value	95% CI
A-HLH Patients	34.178	± 25.950
M-HLH Patients	1069.215	± 1987.409

Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163.

Group	Value	95% CI
A-HLH Patients	1431.488	± 1078.058
M-HLH Patients	878.880	± NA

Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra) Primary · 11 months

Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra.

Group	Value	95% CI
A-HLH Patients	2273.193	± 2383.154
M-HLH Patients	27052.498	± 24009.516

Mean Serum Concentration of White Blood Cells Primary · 11 months

Blood samples was collected at various times after HLH diagnosis to determine the concentration of white blood cells.

Group	Value	95% CI
A-HLH Patients	4.263	± 3.480
M-HLH Patients	2.459	± 2.854

Sponsor's own description

This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hemophagocytic Lymphohistiocytoses

Currently open trials in the same condition.

NCT06160791 — Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) · Phase 2 · recruiting
NCT06585124 — Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas · recruiting
NCT05236764 — Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion · NA · active not recruiting
NCT05882175 — Prospective Validation of the OHI Index · recruiting
NCT03117010 — Prospective Cohort for Adult Hemophagocytosis · recruiting

Other Swedish Orphan Biovitrum trials

Trials by the same sponsor.

NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06992505 — Assessment of Macrophage Activation syndromE in STill's Disease in Italy · completed
NCT06782373 — A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · Phase 2 · recruiting
NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting
NCT06405152 — Assessment of Macrophage Activation syndromE in STill's Disease · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06047210 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swedish Orphan Biovitrum
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06047210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing